SUMO2 antibody (C-Term)

Catalog No. ABIN388085

The Rabbit Polyclonal anti-SUMO2 antibody has been validated for WB and IHC (p). It is suitable to detect SUMO2 in samples from Human. There are 5+ publications available.

Quick Overview for SUMO2 antibody (C-Term) (ABIN388085)

Target: SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SUMO2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB2761

Product Details anti-SUMO2 Antibody

Binding Specificity: AA 63-93, C-Term

Predicted Reactivity: X, Zf, B, C, Ha, Pr, M, Pig, Rat

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This SUMO2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 63-93 amino acids from the C-terminal region of human SUMO2.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-SUMO2 antibody (ABIN388085)

Ito, Nakamura, Mori, Miki, Tanji, Wakabayashi: "Novel eosinophilic neuronal cytoplasmic inclusions in the external cuneate nucleus of humans." in: Neuropathology : official journal of the Japanese Society of Neuropathology, Vol. 36, Issue 5, pp. 441-447, (2017) (PubMed).

Mori, Tanji, Odagiri, Hattori, Hoshikawa, Kono, Yasui, Yokoi, Hasegawa, Kamitani, Yoshida, Wakabayashi: "Ubiquitin-related proteins in neuronal and glial intranuclear inclusions in intranuclear inclusion body disease." in: Pathology international, Vol. 62, Issue 6, pp. 407-11, (2012) (PubMed).

Mori, Miki, Tanji, Ogura, Yagihashi, Jensen, Wakabayashi: "Incipient intranuclear inclusion body disease in a 78-year-old woman." in: Neuropathology : official journal of the Japanese Society of Neuropathology, Vol. 31, Issue 2, pp. 188-93, (2011) (PubMed).

Janer, Werner, Takahashi-Fujigasaki, Daret, Fujigasaki, Takada, Duyckaerts, Brice, Dejean, Sittler: "SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7." in: Human molecular genetics, Vol. 19, Issue 1, pp. 181-95, (2009) (PubMed).

Zhang, Sarge: "Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies." in: The Journal of cell biology, Vol. 182, Issue 1, pp. 35-9, (2008) (PubMed).

Target Details for SUMO2

Target: SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

Alternative Name: SUMO2

Background: SUMO2 is a member of the SUMO (small ubiquitin-like modifier) protein family. This protein family functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. In vertebrates, three members of the SUMO family have been described, SUMO 1 and the functionally distinct homologues SUMO 2 and SUMO 3. SUMO modification sites present in the N terminal regions of SUMO 2 and SUMO 3 are utilized by SAE1/SAE2 (SUMO E1) and Ubc9 (SUMO E2) to form polymeric chains of SUMO 2 and SUMO 3 on protein substrates, a property not shared by SUMO 1.

Molecular Weight: 10871

Gene ID: 6613

NCBI Accession: NP_001005849, NP_008868

UniProt: P61956

Pathways: Methionine Biosynthetic Process